Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

Kari Leigh Keese net worth and biography

Kari Keese Biography and Net Worth

CFO of Axonics

Ms. Keese leads the company’s finance and accounting functions. She joined Axonics in 2014 and previously served as the company’s Director of Finance and Controller. Prior to Axonics, Ms. Keese was a Controller at Vessix Vascular, Inc., a company that was acquired by Boston Scientific in late 2012. Ms. Keese began her career in public accounting and holds a Bachelor of Arts degree in Business Economics from University of California Santa Barbara and a management certification from UCLA Anderson School of Management.

What is Kari Leigh Keese's net worth?: The estimated net worth of Kari Leigh Keese is at least $2.89 million as of January 31st, 2024. Ms. Keese owns 43,323 shares of Axonics stock worth more than $2,889,211 as of April 27th. This net worth approximation does not reflect any other investments that Ms. Keese may own. Learn More about Kari Leigh Keese's net worth.
How do I contact Kari Leigh Keese?: The corporate mailing address for Ms. Keese and other Axonics executives is 26 TECHNOLOGY DRIVE, IRVINE CA, 92618. Axonics can also be reached via phone at (949) 396-6322 and via email at [email protected]. Learn More on Kari Leigh Keese's contact information.
Has Kari Leigh Keese been buying or selling shares of Axonics?: Kari Leigh Keese has not been actively trading shares of Axonics during the last quarter. Most recently, Kari Leigh Keese sold 3,489 shares of the business's stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $67.74, for a transaction totalling $236,344.86. Following the completion of the sale, the chief financial officer now directly owns 43,323 shares of the company's stock, valued at $2,934,700.02. Learn More on Kari Leigh Keese's trading history.
Who are Axonics' active insiders?: Axonics' insider roster includes Juliet Bakker (Director), Raymond Cohen (CEO), Danny Dearen (Insider), Alfred Ford, Jr. (Insider), Kari Keese (CFO), Jane Kiernan (Director), Esteban Lopez (Director), Robert Mcnamara (Director), Karen Noblett (Insider), Rinda Sama (COO), and John Woock (CMO). Learn More on Axonics' active insiders.
Are insiders buying or selling shares of Axonics?: During the last year, insiders at the sold shares 11 times. They sold a total of 121,779 shares worth more than $7,915,525.91. The most recent insider tranaction occured on January, 31st when insider Karen Noblett sold 11,288 shares worth more than $764,649.12. Insiders at Axonics own 1.9% of the company. Learn More about insider trades at Axonics.
Information on this page was last updated on 1/31/2024.

Kari Leigh Keese Insider Trading History at Axonics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/31/2024	Sell	3,489	$67.74	$236,344.86	43,323

Kari Leigh Keese Buying and Selling Activity at Axonics

Axonics Company Overview

Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

Today's Range

Now: $66.69

$66.50

$66.88

50 Day Range

MA: $67.90

$66.47

$69.65

2 Week Range

Now: $66.69

$47.59

$69.68

Volume

318,433 shs

Average Volume

921,149 shs

Market Capitalization

$3.40 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.56